Beyond the Grey Zone: A Physician’s Call for Patient Safety and Evidence-Informed Integrity in BC’s Psychedelic Care
In British Columbia, we are witnessing a profound shift in the mental health landscape. From major headlines to the quiet corners of therapist offices, psychedelic-assisted therapy has moved from the margins into mainstream public interest. As a physician, researcher, and therapist who has spent years stewarding evidence-informed best practice in this field, I’m heartened by the growing recognition that medicines like ketamine, MDMA, and psilocybin may offer meaningful relief for some people struggling with PTSD, depression, chronic pain, and other difficult to treat conditions, particularly when delivered with rigorous screening, ethical psychotherapy, and long-term integration.
However, with this "psychedelic renaissance" comes significant responsibility, and real regulatory uncertainty. Recently, regulatory bodies like the British Columbia College of Social Workers (BCCSW)and the Association of Cooperative Counselling Therapists of Canada (ACCT) have issued guidance regarding scope of practice and legal pathways. While parts of this guidance may be experienced as restrictive—and, in my view, would benefit from clearer definitions and broader consultation—the underlying concern it gestures toward is legitimate: patient safety can be compromised when clinical roles, legal boundaries, and accountability structures are blurred.
A central challenge is that “integration” and “harm reduction” have become umbrella terms used to describe very different practices—ranging from clinically appropriate psychoeducation and post-experience support, to scenarios that edge into facilitation of access or administration outside authorized pathways. I do not assume bad intent; many clinicians are trying to respond to suffering in a system with limited access. But when roles and accountability are ambiguous, patients—often desperate for help—can be placed at avoidable risk. If psychedelic care is to take root within our healthcare system, we need clearer lines between clinically necessary dialogue and prohibited facilitation, and we need inter-professional models where scope, oversight, and standards of care are explicit.
The Relational Container, Ethical Dialogue, and Medical Safety
At the Centre for Medicine Assisted Therapy (CMAT), we deliver psychedelic-assisted care within authorized pathways, with clear role definitions and a rigorous informed-consent framework. A psychedelic experience is not merely a “talk therapy” session enhanced by a substance; it can be a profound physiological, psychological, and relational event, involving profound openness and suggestibility. That reality calls for careful medical and psychological screening, ethical trauma-informed psychotherapy, and continuity of care across the arc of preparation, drug administration sessions, and integration afterward.
When we operate "above-ground" through legal pathways like the Health Canada Special Access Program (SAP), we aren't simply complying with rules—we are building a transparent "safety container" where professional oversight, documentation, emergency planning, and accountability are explicit.
At the same time, these pathways are not always simple or timely. In recent years, access through SAP for medicines such as MDMA (for treatment resistant PTSD) and psilocybin (for treatment resistant depression or end-of-life distress) have become more limited and administratively complex. Many clinicians, ourselves included, have experienced lengthy review periods and iterative requests for clarification before decisions are rendered. When access is slow or uncertain, patients who are suffering can become understandably impatient—and some will seek support elsewhere.
This reality underscores an important point: regulation must not be so risk-averse or administratively burdensome that it inadvertently drives people toward unregulated settings, or chills clinically necessary conversations about contraindications or medication interactions, or trauma vulnerability. We need systems that protect the public, preserve space for harm-reduction dialogue, and respond to clinical urgency with clarity, proportionality, and efficiency.
This model is complex. It requires insurance, safety protocols, medical and psychological screening procedures, informed consent, and specialized training for therapists, counsellors, or social workers holding the work. In our clinic model, three elements remain front and centre:
Medical Oversight: A prescribing physician completes medical and psychological screening, reviews contraindications and medication interactions, and collaborates closely with the pharmacy, nursing and therapy team to ensure continuity of care. In a regulated clinic setting, this role also carries structural responsibilities: establishing and maintaining standard operating procedures for risk management (from hypertension protocols to emergency response), overseeing controlled substance storage and tracking, ensuring emergency equipment readiness, and upholding CPR certification and regulatory compliance across the clinical team. The physician designated as Most Responsible Provider for each patient carries ultimate medical accountability during the course of treatment—clarifying scope boundaries so that therapists and counsellors are not asked to assume medical responsibilities outside their professional training or licensure.
The Power of the Team: By integrating Registered Social Workers and Therapeutic Counsellors alongside prescribers and nurses, clients are held by a diversity of expertise. The psychotherapeutic work - somatic, relationally attuned, evidence- and trauma-informed,- is not an “add-on”; it is central to outcomes and safety, alongside medical and nursing practices.
Ethical Accountability: Practicing within respective scopes ensures professional accountability and valid liability coverage. But the deeper aim is public protection through transparent standards of care, clear documentation, and a culture that prioritizes safety over hype, shortcuts, or overtly risk-averse institutional interpretations of liability.
A Call for Excellence
We can do better for people in British Columbia and across Canada. People living with severe distress—whether related to life-threatening illness, trauma, or moral injury—deserve access to care that does not require navigating legal or clinical grey zones. When access is limited to narrow pathways, inequity grows, and patients may be pushed toward unsupported settings. That reality is exactly why regulation must evolve alongside evidence and clinical realities, rather than defaulting to a prohibitionist posture.
For my fellow clinicians, this is an invitation to collaboration and discernment. We should resist working in silos—and we should resist the false binary of either saying nothing or crossing regulatory lines. It is possible to offer ethical psychoeducation, risk assessment, preparation, and integration while holding firm boundaries around facilitation or administration outside authorized pathways.
To support clinicians navigating this complexity, I’ve developed an Advanced Mentorship and Experiential Training program for Canadian-licensed therapists, social workers, nurses, and prescribers. The apprenticeship is not simply about learning a therapeutic model; it provides real-world immersion in an interdisciplinary clinic operating within regulatory constraints. Trainees gain insight into how collaborative care, medical oversight, documentation standards, and harm-reduction dialogue can coexist within a legally accountable framework. The goal is not just technical competence in medicine assisted therapy, but professional maturity in stewarding this work responsibly in Canada’s evolving landscape.
Harm reduction can also be delivered without facilitating illegal activity. For example, we offer weekly drop-in Group Medical Visits where people can access individualized support and education on psychedelics, legal access pathways, contraindications, and receive integration support—including for those who have had difficult or harmful experiences in underground settings. This kind of education and aftercare improves public safety because it invites disclosure and supports informed decision-making without directing people to illicit supply.
The Path Forward
The future of psychedelic therapy in Canada depends on our ability to be both innovative and accountable. We must steward these medicines with an ethic that is relationship-centered, trauma-informed, and grounded in contemporary science. That includes building above-ground models—and it also includes ensuring that regulatory guidance does not inadvertently discourage disclosure or prohibit clinically necessary conversations that reduce preventable harm. We owe it to patients to do this well while working toward a longer-term framework with Health Canada and provincial regulators that is clearer, more equitable, and better aligned with evidence.
As we look to the horizon, let’s build a standard where authorized, accountable care becomes the norm—and where harm reduction is understood as a legitimate clinical responsibility, not a euphemism for facilitation. We can draw a clear line: providing education, risk assessment, and integration support is ethically necessary; directing patients to illicit supply or structuring “bring-your-own-medicine” models that bypass legal and professional accountability is not. We have research, emerging clinical standards, and workable legal pathways to move forward. Now we need the professional courage to collaborate—strengthening public protection without retreating into silence, stigma, or outdated drug policy paradigms.
Media Contact: Dr. Devon Christie Co-Founder and Medical Director, CMAT devon@cmatbc.com
About CMAT: A Vancouver-based centre of excellence in offering Medicine Assisted Therapy within authorized pathways, integrating psychotherapy with medical oversight and a focus on safety, ethics, and evidence-informed practice. We are dedicated to setting standards of care and generating knowledge in this progressive area of mental healthcare to help clients live authentically, aligned with their values and purpose.
About Dr. Christie: Dr. Devon Christie, MD, RTC, is the Medical Director and Co-Founder of the Centre for Medicine Assisted Therapy (CMAT). She has worked as both a researcher and clinician in the psychedelic field for over a decade, serving as an Investigator and MAPS-certified therapist in clinical trials of MDMA-assisted therapy for PTSD. A family physician with a focused practice in chronic pain and mental health, Dr. Christie is dedicated to stewarding legal, interdisciplinary models of care that bridge traditional medicine and innovative mental health treatments.
